Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This educational activity is supported by an educational grant from: GlaxoSmithKline.

Community Practice Connections™: Real-World Applications for PARP Inhibition in Ovarian Cancer Clinical Practices

Release Date: July 28, 2021
Expiration Date: July 28, 2022

Activity Overview

Currently, there are several PARP inhibitors approved or in clinical development for ovarian cancer. Key trial data will be discussed as well as optimal strategies for incorporating these agents into treatment of patients. PARP inhibitors exhibit a significantly different toxicity profile from traditional chemotherapy agents and therefore key safety data will be carefully addressed.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the recent Reflective Case-Based Oncology Collective™ series. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with ovarian cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live, small group meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This educational activity is supported by an educational grant from: GlaxoSmithKline.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

The live activity series is directed toward medical oncologists who treat or manage patients with ovarian cancer. Surgical and radiation oncologists, pathologists, fellows, nurses, nurse practitioners, physician assistants, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate in the online activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:
  • Assess strategies utilized to integrate molecular testing with respect to current evidence and guidelines-based molecular testing recommendations for treatment selection in patients with newly diagnosed and recurrent ovarian cancer
  • Review the role of PARP inhibitors for patients with ovarian cancer in maintenance and treatment setting based on emerging data and evolving trends
  • Identify strategies utilized in the community to manage treatment-related toxicities associated with PARP inhibitor use and ensure these approaches are in line with guideline-based recommendations
  • Reflect on recent evidence and expert opinion guidance to incorporate state-of-the-art approaches to care for women with advanced ovarian cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Program Chair


Robert L. Coleman, MD, FACOG, FACS
Robert L. Coleman, MD, FACOG, FACS
Gynecologic Oncologist and Chief Scientific Officer
US Oncology Research
The Woodlands, TX

Disclosures: Grant/Research Support: ImmunoGen, Genmab/Seagen, AstraZeneca, Clovis Oncology, Merck & Co.; Consultant: Immunogen, Genmab/Seagen, AstraZeneca, Clovis Oncology, Merck & Co., GlaxoSmithKline, Toray, Deciphera Pharmaceuticals, Gradalis.

Ursula A. Matulonis, MD
Ursula A. Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: Merck, NextCure, Novartis; Other: Honorarium for speaking engagements from Merck.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By